Lilly, Boehringer's Jardiance bags FDA approval for heart failure
The FDA has expanded the label for Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) to include reducing the risk of cardiovascular death plus hospitalisation for heart failure (HF) in adult patients with reduced ejection fraction (HFrEF).
August 19, 2021
by firstwordpharma
Novatek Requalified as Supplier for Boehringer Aseptic Mfg. Facilities
Novatek's regulatory compliant quality solutions used at Boehringer for human pharma, animal health and biopharmaceutical sterile manufacturing sites.
May 27, 2021
by contractpharma
Boehringer to Acquire NBE-Therapeutics in €1.2B Transaction
PPF Group, an international investment group, has signed an agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim.
December 11, 2020
by contractpharma
Bridge Biotherapeutics terminates collaboration agreement with Boehringer
Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed to terminate their previously signed collaboration and licence agreement to develop BBT-877.
November 11, 2020
by pharmaceutical-technology
EC approves new indication for Boehringer’s nintedanib in pulmonary fibrosis
Boehringer Ingelheim has secured approval for a new indication of nintedanib to treat adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).
July 17, 2020
by pharmaceutical-business-review
Boehringer to sell stake in Hikma
Boehringer Ingelheim Invest has announced plans to pull its investment in Hikma Pharmaceuticals.
June 24, 2020
by pharmatimes
Boehringer and CDR-Life to develop geographic atrophy therapies
Boehringer Ingelheim has signed a collaboration and licensing agreement with CDR-Life for the research and development of antibody fragment-based therapeutics to treat geographic atrophy (GA).
May 15, 2020
by pharmaceutical-technology
Insilico and Boehringer to use AI for drug targets discovery
Boehringer partners Insilico for AI-based discovery of drug targets. Insilico Medicine has partnered with Boehringer Ingelheim.
April 16, 2020
by pharmaceutical-technology
FDA hands Boehringer and Lilly complete response letter for insulin adjunct
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
March 26, 2020
Boehringer, Lilly Get Complete Response Letter for Empagliflozin
FDA is unable to approve sNDA for Empagliflozin in type 1 diabetes.
March 24, 2020
by contractpharma
BioMed X Starts New Schizophrenia Research Program with Boehringer Ingelheim
BioMed X announced the start of a new joint research group in collaboration with Boehringer Ingelheim at the BioMed X Innovation Center in Heidelberg.
January 16, 2020
by b3cnewswire
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint
Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company (Lilly), failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure.
December 20, 2019
by pharmaceutical-business-review